ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Premonition or Opportunity?

<< Previous

Bullboard Posts

Next >>

Post by Speculativefoolon Jan 19, 2022 10:42am

271 Views

Post# 34332562

Premonition or Opportunity?

I woke up @3am last night fretting about how deep underwater I am w/PMN (I'm not BS-ing) and have woken up to this announcement. Now I'm wondering if this is yet another bone thrown out to pacify us OR is it an opportunity to sell at least some of my shares (before the inevitable? price fall in the coming weeks) OR is this a SUBSTANTIVE step forward. Would really appreciate the thoughts of more experienced Promis investors as I've lost confidence in such "exciting" announcements.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario